In this randomised , double-blind , placebo-controlled , exploratory , proof-of-concept phase 2 trial , patients aged 18-55 years with five to 14 migraine days per 28-day period were randomly assigned ( 1:1 ) via an interactive web response system to receive an intravenous dose of ALD403 1000 mg or placebo .